Cover Image

Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye: forum

Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how m...

Full description

Saved in:
Bibliographic Details
Main Authors: Koh, Gou Young (Author) , Augustin, Hellmut (Author) , Campochiaro, Peter (Author)
Format: Article (Journal) Editorial
Language:English
Published: May 2022
In: Trends in molecular medicine
Year: 2022, Volume: 28, Issue: 5, Pages: 347-349
ISSN:1471-499X
DOI:10.1016/j.molmed.2022.03.004
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.molmed.2022.03.004
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1471491422000727
Get full text
Author Notes:Gou Young Koh, Hellmut G. Augustin, and Peter A. Campochiaro
Description
Summary:Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
Item Description:Online verfügbar: 5 April 2022, Artikelversion: 28 April 2022
Gesehen am 26.02.2024
Physical Description:Online Resource
ISSN:1471-499X
DOI:10.1016/j.molmed.2022.03.004

Similar Items